¶ Braak Staging and Tau Propagation Pathway
The Braak staging system is a neuropathological classification scheme that describes the progressive spread of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein through the brain in Alzheimer's disease (AD). Developed by Heiko and Eva Braak in the 1990s, this staging system provides a standardized framework for understanding the anatomical progression of tau pathology and its relationship to clinical symptoms.
The Braak staging system recognizes six stages (I-VI) of tau pathology progression, beginning in transentorhinal regions and ultimately affecting isocortical areas in advanced stages. This pathway documents the molecular mechanisms, anatomical progression, and clinical implications of tau propagation in neurodegeneration.
Heiko Braak and Eva Braak published their landmark staging system in 1991, based on examination of over 2,000 brains. Their work established that:
- Neurofibrillary tangles follow a predictable pattern of progression
- The earliest changes occur in the entorhinal cortex
- Progression follows anatomically connected neural networks
- The stage of pathology correlates with cognitive impairment
This system has become one of the most important neuropathological criteria for diagnosing AD, forming the "B" component of the ABC score (A = Amyloid plaques, B = Braak NFT staging, C = CERAD neuritic plaque density).
flowchart TD
A[Stage I-II<br/>Transentorhinal] --> B[Stage III-IV<br/>Limbic]
B --> C[Stage V-VI<br/>Isocortical]
A --> A1[Entorhinal Cortex]
A --> A2[Perirhinal Cortex]
A --> A3[Hippocampus CA1]
B --> B1[Amygdala]
B --> B2[Hippocampus Proper]
B --> B3[Thalamus]
B --> B4[Locus Coeruleus]
C --> C1[Frontal Cortex]
C --> C2[Temporal Cortex]
C --> C3[Parietal Cortex]
C --> C4[Occipital Cortex]
The earliest tau pathology appears in the transentorhinal region and entorhinal cortex, which serve as the gateway to the hippocampal formation. At this stage:
- Neurofibrillary changes are limited to the pre-α layer of the entorhinal cortex
- The perirhinal cortex shows pretangle material
- Minimal to no cognitive symptoms typically present
- Often occurs in individuals as young as 20-30 years
Key structures affected:
- Entorhinal cortex
- Transentorhinal region
- Perirhinal cortex
Tau pathology spreads to the limbic system, including the hippocampus and amygdala:
Stage III:
- Pathology extends into the hippocampal formation
- Ammon's horn (CA1) and subiculum affected
- Beginning of memory impairment symptoms
- Strong correlation with mild cognitive impairment (MCI)
Stage IV:
- Extensive hippocampal involvement
- Amygdala shows significant pathology
- Locus coeruleus degeneration begins
- Moderate to severe memory deficits evident
- Clear clinical diagnosis of AD possible
Key structures affected:
Tau pathology spreads throughout the neocortex, affecting all brain regions:
Stage V:
- Frontal, temporal, and parietal cortices heavily affected
- Primary visual cortex (V1) typically spared until late stage
- Severe cognitive impairment
- Global dementia symptoms
Stage VI:
- Complete neocortical involvement
- Primary sensory and motor cortices affected
- Most severe deficits in all cognitive domains
- Near-total loss of functional independence
Key structures affected:
- Frontal cortex
- Temporal cortex
- Parietal cortex
- Occipital cortex
Tau protein exhibits prion-like properties, propagating through neural networks via:
- Seed-dependent aggregation: Pathological tau can template the conversion of normal tau into insoluble aggregates
- Synaptic transmission: Tau is released synaptically and taken up by connected neurons
- Intercellular transfer: Extracellular tau can enter cells through various receptors
Research from SEA-AD papers demonstrates that different AD subtypes show distinct tau conformational strains, suggesting variations in propagation mechanisms.
The Epidemic Spreading Model (ESM) describes tau spread through functional brain networks:
- Pathology follows patterns of functional connectivity
- Regions with high connectivity receive more pathological "seeds"
- Network topology influences regional vulnerability
- This explains why some regions are affected earlier than others
Tau can propagate through:
- Anterograde transport: Moving from cell body to axon terminals
- Retrograde transport: Moving from terminals back to cell body
- Exosome release: Extracellular vesicles containing tau
The formation of neurofibrillary tangles involves:
- Hyperphosphorylation of tau by kinases (GSK3β, CDK5, MARK)
- Reduced microtubule binding affinity
- Tau misfolding and aggregation
- Formation of paired helical filaments (PHFs)
Key proteins involved:
SEA-AD research demonstrates that amyloid-β (Aβ) plaque deposition is necessary for the expanded distribution of NFTs to reach isocortical Braak stages V/VI. However:
- Aβ and tau pathology can occur independently
- Tau pathology can exist without significant Aβ (primary age-related tauopathy - PART)
- The relationship between Aβ and tau remains an active research area
According to the amyloid-tau-neurodegeneration (AT(N)) framework:
- First: Amyloid abnormalities (CSF Aβ42, PET)
- Second: Tau abnormalities (CSF p-tau, PET)
- Third: Structural brain changes (MRI atrophy)
| Braak Stage |
Typical Symptoms |
| I-II |
Normal cognition, subtle memory changes |
| III-IV |
Mild cognitive impairment, memory deficits |
| V-VI |
Moderate to severe dementia |
The regional distribution of tau pathology correlates strongly with:
- Memory impairment (hippocampal involvement)
- Executive dysfunction (frontal cortex involvement)
- Language deficits (temporal cortex involvement)
- Visuospatial deficits (parietal cortex involvement)
Modern tau PET tracers allow visualization of tau pathology in vivo:
- Flortaucipir (AV-1451/T807): FDA-approved tracer that selectively binds to PHF tau
- 18F-MK-6240: Next-generation tau PET tracer
- GTP1 (Gu Tsai PET 1): Binds to 4R tau aggregates
Research shows that tau PET uptake patterns in living patients reflect pathological Braak staging.
¶ Locus Coeruleus and Early Tau Pathology
The locus coeruleus is one of the earliest sites of tau accumulation in AD:
- Pretangle stages occur before any cortical tau pathology
- LC degeneration leads to decreased norepinephrine release
- Loss of neuroprotective effects against Aβ-induced toxicity
- Contributes to sleep-wake cycle disruption in early AD
- Anti-tau antibodies: Passive immunization approaches
- Small molecule inhibitors: Tau aggregation inhibitors
- Kinase inhibitors: Targeting tau phosphorylation enzymes
- Synaptic protection: Preventing trans-synaptic spread
Multiple trials target tau pathology at various stages:
- Tau PET as inclusion criterion
- Anti-tau immunotherapies in Phase II/III
- Combination therapies targeting both Aβ and tau
See Clinical Trials and Drug Pipeline for current therapeutic approaches.
¶ Research Gaps and Open Questions
- What determines individual variation in Braak stage progression rate?
- Can we identify early predictors of rapid tau spread?
- What is the exact relationship between tau strains and clinical phenotypes?
- Can we develop interventions to slow or halt tau propagation?
- What role do glial cells play in tau spread?
See Research Priorities for more open questions in the field.
- Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)
- Montine et al., National Institute on Aging-Alzheimer's Association criteria (2012)
- Braak et al., Preclinical AD (2006)
- SEA-AD Research, Tau conformational strains in AD (2024)
- Sepulveda-Falla et al., Tau propagation via epidemic spreading model (2022)
- Thalhauser et al., Amyloid dependency of NFT distribution (2024)
- Jack et al., AT(N) framework for Alzheimer's disease (2019)
- Tau PET and Braak staging correlation (2022)
- Locus coeruleus tau in early AD (2024)
This page was created using evidence from SEA-AD paper extractions and represents current scientific understanding of Braak staging and tau propagation mechanisms.
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
9 references |
| Replication |
0% |
| Effect Sizes |
50% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
75% |
Overall Confidence: 46%